Keynote speakers

 

 

OPENING SESSION (Saturday PM)

 

William C Hahn, MD, PHD

Associate Professor of Medicine, Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute

Institute Member, Broad Institute of MIT and Harvard

 

Dr. William C. Hahn received his M.D. and Ph.D. degrees from Harvard University and completed his clinical training at the Massachusetts General Hospital and Dana-Farber Cancer Institute. He performed his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute for Biomedical Research. He is a faculty member in the Department of Medical Oncology at the Dana-Farber Cancer Institute and an Institute Member of the Broad Institute of MIT and Harvard. He co-directs the Center for Cancer Genome Discovery, is the Chief of the Division of Molecular and Cellular Oncology and is the Chair of the Executive Committee for Research at the Dana-Farber Cancer Institute. Dr. Hahn’s research focuses on how mutations cooperate to program cancer initiation and progression. His laboratory has created innovative experimental models and genome scale tools to interrogate gene function. Dr. Hahn has served as the President for the American Society for Clinical Investigation and was the recipient of the Ho-Am Prize in Medicine in 2010. 

 

 

 

 

Peter A Jones, PHD

Director Norris Comprehensive Cancer Center, Department of Urology, University of Southern California (Los Angeles)

 

 

 

CLOSING SESSION (Thursday PM)

 

Myles Brown, MD

Director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School, Boston, MA

 

Myles Brown received his BS in Biology from Yale and his MD from Johns Hopkins. He completed clinical training in Internal Medicine at the Brigham and Women’s Hospital and in Medical Oncology at the Dana-Farber Cancer Institute. He joined the faculty of Dana-Farber and Harvard Medical School in 1991 where he became a Professor of Medicine in 2006. From 2002-2010 he was the Chief of the Division of Molecular and Cellular Oncology at the Dana-Farber. In 2010 together with Shirley Liu he founded the Center for Functional Cancer Epigenetics at the Dana-Farber to facilitate the development of new therapies targeting the cancer epigenome. His laboratory has made seminal contributions that have uniquely reformulated the understanding of steroid hormone action in normal physiology and in the hormone dependence of breast and prostate cancers. Among his many honors are the 2004 North American Menopause Society/Wyeth Pharmaceuticals SERM Research Award and the 2010 Edwin B. Astwood Award of the Endocrine Society. He was elected to the American Society for Clinical Investigation in 1997, the Association of American Physicians in 2003 and as a Fellow of the American Association for the Advancement of Science in 2014.